<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-type="olc" bill-stage="Introduced-in-Senate" dms-id="A1" public-private="public" slc-id="S1-OTT25047-355-PJ-G2T"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>119 S1891 IS: Producing Incentives for Long-term production of Lifesaving Supply of medicine Act</dc:title>
<dc:publisher>U.S. Senate</dc:publisher>
<dc:date>2025-05-22</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">II</distribution-code><congress>119th CONGRESS</congress><session>1st Session</session><legis-num>S. 1891</legis-num><current-chamber>IN THE SENATE OF THE UNITED STATES</current-chamber><action><action-date date="20250522">May 22, 2025</action-date><action-desc><sponsor name-id="S374">Mr. Cotton</sponsor> introduced the following bill; which was read twice and referred to the <committee-name committee-id="SSFI00">Committee on Finance</committee-name></action-desc></action><legis-type>A BILL</legis-type><official-title>To amend the Internal Revenue Code of 1986 to establish the generic drugs and biosimilars production credit, and for other purposes.</official-title></form><legis-body style="OLC" display-enacting-clause="yes-display-enacting-clause" id="H62F75B8F3DD24D2E9296B814C0E3EA96"><section section-type="section-one" id="H901B580E5530485684C9F44851A53BD2"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Producing Incentives for Long-term production of Lifesaving Supply of medicine Act</short-title></quote> or the <quote><short-title>PILLS Act</short-title></quote>.</text></section><section id="H1C535AD977E04A46A33C7455DAB20D91"><enum>2.</enum><header>Generic drugs and biosimilars production credit</header><subsection id="HDA87B20281904FBB86370D91CF7105DE"><enum>(a)</enum><header>In general</header><text>Subpart D of part IV of subchapter A of <external-xref legal-doc="usc-chapter" parsable-cite="usc-chapter/26/1">chapter 1</external-xref> of the Internal Revenue Code of 1986 is amended by adding at the end the following new section: </text><quoted-block style="OLC" id="H84D4CE758AA743D8B3A6740C384428B8"><section id="HFBE7C6C05C8D4DC295D7691AFFA4A731"><enum>45BB.</enum><header>Generic drugs and biosimilars production credit</header><subsection id="H00040355208E4EF88FC14F3F9A867206"><enum>(a)</enum><header>In general</header><paragraph id="HEDC48B57D88649B281DA10AF06EC0366"><enum>(1)</enum><header>Allowance of credit</header><text>For purposes of section 38, the generic drugs and biosimilars production credit for any taxable year is an amount equal to the credit amount determined under subsection (b) with respect to each eligible component which is—</text><subparagraph id="H8E50798D5D6B4CFAA09156E53540D12C"><enum>(A)</enum><text>produced by the taxpayer in the United States, and</text></subparagraph><subparagraph id="H558A92E49BC54C049E0152BEF41C7A11"><enum>(B)</enum><text display-inline="yes-display-inline">sold by such taxpayer to an unrelated person (as determined by the Secretary) during the taxable year.</text></subparagraph></paragraph><paragraph id="H8509374EB5BC40EFBCC3B7E06110EDAC"><enum>(2)</enum><header>Production and sale must be in trade or business</header><text>Rules similar to the rules of section 45X(a)(2) shall apply.</text></paragraph><paragraph id="HE0F6EC0C51EC4A3F9AC5C76A9C839F08"><enum>(3)</enum><header>Disallowance of credit</header><text display-inline="yes-display-inline">The credit under this subsection shall not be allowed to any taxpayer which, at any time during the taxable year, was a foreign entity of concern (as defined in section 9901(8) of the William M. (Mac) Thornberry National Defense Authorization Act for Fiscal Year 2021 (<external-xref legal-doc="usc" parsable-cite="usc/15/4651">15 U.S.C. 4651</external-xref>)).</text></paragraph></subsection><subsection id="HEEEB636688D54302833E758C490A4679"><enum>(b)</enum><header>Credit amount</header><text>For purposes of this section—</text><paragraph id="HC639FD1FC02C437BA4D154A113A2822F"><enum>(1)</enum><header>In general</header><text>Subject to paragraph (4), the amount determined under this subsection with respect to any eligible component is an amount equal to the base credit percentage of the value added to such component by the taxpayer.</text></paragraph><paragraph commented="no" id="HE149D726786741F184C5EEF41C8E692F"><enum>(2)</enum><header>Value added</header><text>The value added to a component by a taxpayer is an amount equal to—</text><subparagraph commented="no" id="HBBE0D5C52355476EAACAEC18A3BB4714"><enum>(A)</enum><text>the gross receipts received by the taxpayer from the sale of the eligible component, minus</text></subparagraph><subparagraph commented="no" id="HEC1FB920AF8B4573AC57B2429D1CD017"><enum>(B)</enum><text>the cost of eligible components purchased from an unrelated person in connection with the production of the component by the taxpayer.</text></subparagraph></paragraph><paragraph id="H9326F679DACC42E091DCD362E472EE1F"><enum>(3)</enum><header>Base credit percentage</header><subparagraph id="H1E3DDD27CC1E45E4A672EC377CC3E61F"><enum>(A)</enum><header>In general</header><text>Except as provided in subparagraphs (B) and (C), the base credit percentage is 30 percent.</text></subparagraph><subparagraph id="H33D75AEC88F9465586E22E8F3CB1C37E"><enum>(B)</enum><header>Increased base credit percentage for certain eligible components</header><text>The base credit percentage is 35 percent in the case of the final production of—</text><clause id="HDD1AA9D3F1474594915111325201E117"><enum>(i)</enum><text>a drug substance, </text></clause><clause id="H98F861F517314DC49489FAFCC26B1F14"><enum>(ii)</enum><text display-inline="yes-display-inline">a drug product, or </text></clause><clause id="H83F86B4570E646FE9A84C7C9FC37CB97"><enum>(iii)</enum><text display-inline="yes-display-inline">a biological product.</text></clause></subparagraph><subparagraph commented="no" id="H8EA17042A57C4E159CABA0F1EA6C357B"><enum>(C)</enum><header>Domestic content bonus credit</header><clause commented="no" id="HD48155E9F4234A06A0E699103640CE25"><enum>(i)</enum><header>In general</header><text display-inline="yes-display-inline">In the case of an eligible component which contains domestic content, the base credit percentage determined under this paragraph (determined without regard to this subparagraph) shall be increased by an amount equal to—</text><subclause commented="no" id="H4DA9330E4DE34A33BC5725F7C0D12220"><enum>(I)</enum><text>the domestic content percentage, multiplied by</text></subclause><subclause commented="no" id="HCDE7FF0D2D614F48A8E5B2868B6A911C"><enum>(II)</enum><text>0.20.</text></subclause></clause><clause commented="no" id="H65ABDDE8C203461FA30D6012A247DEC4"><enum>(ii)</enum><header>Domestic content percentage</header><text>For purposes of this subparagraph, the term <term>domestic content percentage</term> means the percentage of the total cost of the eligible components taken into account for purposes of paragraph (2) which is attributable to materials and components that were produced in the United States.</text></clause><clause commented="no" id="HE68B53F4E3CF4D409A240A9F82D3BB58"><enum>(iii)</enum><header>Documentation rules</header><subclause commented="no" id="HA57E0DCAACEB40BDA1AC6C809D345EC3"><enum>(I)</enum><header>Record keeping</header><text>No domestic content bonus credit shall be determined under this subparagraph unless the taxpayer provides documentation supporting the domestic content percentage (in such form and manner as the Secretary shall prescribe). </text></subclause><subclause commented="no" id="H03B78E90EF35465F9072FC16FB78768C"><enum>(II)</enum><header>Certification by unrelated party</header><text display-inline="yes-display-inline">In the case of materials or components provided to the taxpayer by an unrelated party, the Secretary shall accept certification (in such form and manner as the Secretary shall prescribe) by such unrelated party that the materials or components were produced in the United States. </text></subclause></clause></subparagraph></paragraph><paragraph id="HA0245FD304B049448702B7095460CEC6"><enum>(4)</enum><header>Phase out</header><subparagraph id="H4DEFB67FD66A4FD2B1E7A5E4684CF921"><enum>(A)</enum><header>In general</header><text>In the case of any eligible component sold after December 31, 2030, the amount determined under this subsection with respect to such component shall be equal to the product of—</text><clause id="HD25A46056CAD43CF8F4DF512450CBAFC"><enum>(i)</enum><text>the amount determined under paragraph (1) with respect to such component (determined without regard to this paragraph and after the application of paragraphs (2) and (3)), and</text></clause><clause id="H8224B227BCB34F8BB1FF19A42D747230"><enum>(ii)</enum><text>the phase out percentage.</text></clause></subparagraph><subparagraph id="H38BAEC50730043C0BE88B9AB2F94E26E"><enum>(B)</enum><header>Phase out percentage</header><text>For purposes of subparagraph (A), the phase out percentage is—</text><clause id="HD2D481768CA94322A6A8FCD60E9317F3"><enum>(i)</enum><text>in the case of an eligible component sold during calendar year 2031, 75 percent,</text></clause><clause id="H017001755F754E73824AEB49CB52F17E"><enum>(ii)</enum><text>in the case of an eligible component sold during calendar year 2032, 50 percent,</text></clause><clause id="HD40A311A77164D918FF350C14C161B3F"><enum>(iii)</enum><text>in the case of an eligible component sold during calendar year 2033, 25 percent, and</text></clause><clause id="HB4A6124C93EE49F895C1A06E14D841EF"><enum>(iv)</enum><text>in the case of an eligible component sold after December 31, 2033, 0 percent.</text></clause></subparagraph></paragraph></subsection><subsection id="H2258361A650E4110ADDFF5902A45AA66"><enum>(c)</enum><header>Definitions</header><text>For purposes of this section—</text><paragraph id="HFBFC4F800E1941799BBA94B2883D795D"><enum>(1)</enum><header>Eligible component</header><subparagraph id="HF0FAED78CE31404494BE29E4DFFC9594"><enum>(A)</enum><header>In general</header><text>Except as provided in subparagraphs (B) and (C), the term <term>eligible component</term> means—</text><clause id="HD704C96C9AEA47F79771CEB44919341D"><enum>(i)</enum><text>an approved generic drug,</text></clause><clause id="HCD12B98F4E7F470CA0E47979EF1EFB44"><enum>(ii)</enum><text>a licensed biosimilar, and</text></clause><clause id="H06432CE8B8424841B0ECCCFFF120F5E8"><enum>(iii)</enum><text>any drug substance, intermediate raw material, starting material, reagent, component, in-process material, inactive ingredient, container closure system, packaging, quality testing, or other material or service used, or sold with intention for use, in the production of an approved generic drug or a licensed biosimilar.</text></clause></subparagraph><subparagraph display-inline="no-display-inline" id="HAB40EEFE965B4F6EA6D7C7EC75A86EFC"><enum>(B)</enum><header>Exclusion of certain components</header><text>The term <term>eligible component</term> shall not include a component any portion of the production of which occurred at a facility which is the subject of a warning letter—</text><clause id="H9691985A3341460E8E3A70A4EE6E3C3D"><enum>(i)</enum><text>which was issued by the Food and Drug Administration on or after September 1, 2009, and</text></clause><clause id="H5290D26A06F04A07A7D79BCB6FB08AC3"><enum>(ii)</enum><text>with respect to which the Food and Drug Administration has not issued a close-out letter.</text></clause></subparagraph><subparagraph id="H43252CF7F85E4808AB0417D5047D33EB"><enum>(C)</enum><header>Application with other credits</header><text>The term <term>eligible component</term> shall not include any property which is produced at a facility if the basis of any property which is part of such facility is taken into account for purposes of the credit allowed under section 48F after the date of the enactment of this section.</text></subparagraph></paragraph><paragraph id="H05F5352192C540568283E32B6209A40B"><enum>(2)</enum><header>Approved generic drug</header><text>The term <term>approved generic drug</term> means—</text><subparagraph id="H11177947E2A843E2A4EF0BB0DBDAB1F6"><enum>(A)</enum><text>a drug for which an approval of an application filed under section 505(j) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355(j)</external-xref>) is in effect, or</text></subparagraph><subparagraph id="H566369CBD3614607B1CC1328301A14C0"><enum>(B)</enum><text display-inline="yes-display-inline">an authorized generic drug (as defined in section 314.3 of title 21, Code of Federal Regulations (or any successor regulation)).</text></subparagraph></paragraph><paragraph id="H2B958039048B45A98328CEDAD8DEE9E8"><enum>(3)</enum><header>Licensed biosimilar</header><subparagraph id="idA4151643609B40A883B5204F57D8BA89"><enum>(A)</enum><header>In general</header><text display-inline="yes-display-inline">The term <term>licensed biosimilar</term> means a biological product for which a biologics license has been issued under section 351(k) of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/262">42 U.S.C. 262(k)</external-xref>). </text></subparagraph><subparagraph commented="no" id="HFBDA9177821A46ACB16D33B0BD07FA6F"><enum>(B)</enum><header>Biological product</header><text display-inline="yes-display-inline">The term <term>biological product</term> has the meaning given such term in section 351(i)(1) of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/262">42 U.S.C. 262(i)(1)</external-xref>). </text></subparagraph></paragraph><paragraph id="H5283BD500C9949C8B1984F9D26C947FB"><enum>(4)</enum><header>Other terms</header><text display-inline="yes-display-inline">The terms <term>drug substance</term> and <term>drug product</term> have the respective meanings given such terms in section 314.3 of title 21, Code of Federal Regulations (or any successor regulation). </text></paragraph><paragraph id="H8BCAE28C0C4147E7B1D306B2CC7F0738"><enum>(5)</enum><header>Produced in the United States</header><text>The term <term>produced in the United States</term> means that all the production of the material or component takes place in the United States, regardless of the origin of the subcomponents of such material or component. </text></paragraph><paragraph id="H3FE826E4D5A0459C89B10E284CB70BFD"><enum>(6)</enum><header>Production</header><text display-inline="yes-display-inline">The term <term>production</term> means all steps in the manufacture, propagation, and preparation of an eligible component, including synthesis, mixing, granulating, milling, molding, lyophilizing, tableting, encapsulating, coating, sterilizing, testing, filling, labeling, packaging, and storage prior to release by the manufacturer.</text></paragraph></subsection><subsection id="HF75430FF70C54C8EA86C235B2996F209"><enum>(d)</enum><header>Special rules</header><text display-inline="yes-display-inline">Rules similar to the rules of paragraphs (1), (3), and (4) of section 45X(d) shall apply.</text></subsection><subsection commented="no" display-inline="no-display-inline" id="id3de988314a034789983d646c3bd8b1f9"><enum>(e)</enum><header>Regulatory authority</header><text display-inline="yes-display-inline">The Secretary shall prescribe such regulations and other guidance as are appropriate or necessary to carry out the purposes of this section.</text></subsection></section><after-quoted-block>.</after-quoted-block></quoted-block></subsection><subsection id="H000BFB723099422E8A6EECE21988FDFC"><enum>(b)</enum><header>Elective payment</header><paragraph commented="no" display-inline="no-display-inline" id="idd60b0c20b5fe4a2fab603cac6aee8295"><enum>(1)</enum><header>In general</header><text display-inline="yes-display-inline"><external-xref legal-doc="usc" parsable-cite="usc/26/6417">Section 6417(b)</external-xref> of the Internal Revenue Code of 1986 is amended by adding at the end the following new paragraph:</text><quoted-block style="OLC" display-inline="no-display-inline" id="HB7E3A745AC9041C089F3E2B94181244F"><paragraph id="H9FEB451E2A4B4EAFADDBD9F9E94218FA"><enum>(13)</enum><text display-inline="yes-display-inline">The generic drugs and biosimilars production credit determined under section 45BB.</text></paragraph><after-quoted-block>.</after-quoted-block></quoted-block></paragraph><paragraph commented="no" display-inline="no-display-inline" id="id6b75bbdceba14ba58659d9277600b5c0"><enum>(2)</enum><header>Election with respect to other entities</header><text>Paragraph (1) of section 6417(d) is amended—</text><subparagraph commented="no" display-inline="no-display-inline" id="idc9ff09cf269a4ecf80aed4596bba249b"><enum>(A)</enum><text display-inline="yes-display-inline">by redesignating subparagraph (E) as subparagraph (F),</text></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="id819c5f8584f74cfc8737c4557cd1697f"><enum>(B)</enum><text>by striking <quote>or (D)</quote> each place it appears in subparagraph (F), as so redesignated, and inserting <quote>(D), or (E)</quote>, and</text></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="id56d84c0944234e5e92b9005a3614624d"><enum>(C)</enum><text>by inserting after subparagraph (D) the following new subparagraph:</text><quoted-block style="OLC" display-inline="no-display-inline" id="id74962eb2e13f49a58810ba6ed30553e6"><subparagraph id="id6a0d2baa78914ec6850ea4e6e9b895b9"><enum>(E)</enum><header>Election with respect to generic drugs and biosimilars production credit</header><clause id="idd4468af7f5cb458f9a63173ccb946c23"><enum>(i)</enum><header>In general</header><text>If a taxpayer other than an entity described in subparagraph (A) makes an election under this subparagraph with respect to any taxable year in which such taxpayer has, after December 31, 2024, produced eligible components (as defined in section 45BB(c)(1)), such taxpayer shall be treated as an applicable entity for purposes of this section for such taxable year, but only with respect to the credit described in subsection (b)(13).</text></clause><clause commented="no" display-inline="no-display-inline" id="id4c4178c92c7147608bb82a7bdda8ad3a"><enum>(ii)</enum><header>Other rules</header><text display-inline="yes-display-inline">The rules of clauses (ii) and (iii) of subparagraph (D) shall apply for purposes of this subparagraph.</text></clause></subparagraph><after-quoted-block>.</after-quoted-block></quoted-block></subparagraph></paragraph></subsection><subsection id="id0fe0e961b2d247cf94fd05a54ea13c6b"><enum>(c)</enum><header>Transfer of credits</header><text><external-xref legal-doc="usc" parsable-cite="usc/26/6418">Section 6418(f)(1)A)</external-xref> of the Internal Revenue Code of 1986 is amended by adding at the end the following new clause:</text><quoted-block style="OLC" display-inline="no-display-inline" id="id892a3405a7d5471ab3130d083a8c367f"><clause id="id47c83010b2a94ceab2e597975ae5f2ed"><enum>(xii)</enum><text>The generic drugs and biosimilars production credit determined under section 45BB.</text></clause><after-quoted-block>.</after-quoted-block></quoted-block></subsection><subsection id="HCB77DEE759824BDFA19EAB60F85FC8D5"><enum>(d)</enum><header>Conforming amendments</header><paragraph id="HFFFB289D5B7A4EB2B37ED2A648168E1D"><enum>(1)</enum><text><external-xref legal-doc="usc" parsable-cite="usc/26/38">Section 38(b)</external-xref> of the Internal Revenue Code of 1986 is amended—</text><subparagraph id="HA12CF5843E004EFB93C6F97D5213761E"><enum>(A)</enum><text>by striking <quote>plus</quote> at the end of paragraph (40),</text></subparagraph><subparagraph id="HEEDE813AF2574C00AF858BD44CD312D1"><enum>(B)</enum><text>by striking the period at the end of paragraph (41) and inserting <quote>, plus</quote>, and </text></subparagraph><subparagraph id="idBAB4A2F5CF734A339F9386053FC05C9D"><enum>(C)</enum><text>by adding at the end the following new paragraph:</text><quoted-block style="OLC" id="H1D7B5B91376945C6BBC0F29613BEEB8F"><paragraph id="H8574D330F0414491BF9DB2F3D4B751B3"><enum>(42)</enum><text>the generic drugs and biosimilars production credit determined under section 45BB(a).</text></paragraph><after-quoted-block>.</after-quoted-block></quoted-block></subparagraph></paragraph><paragraph id="H2034F94D0688463492F26B77AD3CA772"><enum>(2)</enum><text>The table of sections for subpart D of part IV of subchapter A of <external-xref legal-doc="usc-chapter" parsable-cite="usc-chapter/26/1">chapter 1</external-xref> of the Internal Revenue Code of 1986 is amended by adding at the end the following new item:</text><quoted-block style="OLC" id="HAADA41855B69412EBAFB9C9AE954D09B"><toc regeneration="no-regeneration"><toc-entry level="section">Sec. 45BB. Generic drugs and biosimilars production credit.</toc-entry></toc><after-quoted-block>.</after-quoted-block></quoted-block></paragraph></subsection><subsection id="H95E1FE3EA0F04B4FB3DF72FACB6F1E52"><enum>(e)</enum><header>Effective date</header><text>The amendments made by this section shall apply to generic drugs and biologics produced after the date of enactment of this Act.</text></subsection></section><section id="HBC31822995DB4C1081610F505364C236"><enum>3.</enum><header>Generic drugs and biosimilars investment credit</header><subsection id="HAD01C2D3F09948F5B4AC0A169709A9FF"><enum>(a)</enum><header>In general</header><text>Subpart E of part IV of subchapter A of <external-xref legal-doc="usc-chapter" parsable-cite="usc-chapter/26/1">chapter 1</external-xref> of the Internal Revenue Code of 1986 is amended by inserting after section 48E the following new section:</text><quoted-block style="OLC" id="H873ADF4661254759BFFF678F8F524531"><section id="HB7581B261F4C4BDFB1BFF1541D94D5C1"><enum>48F.</enum><header>Generic drugs and biosimilars investment credit</header><subsection id="H30A71DB354DB439A9788CF3E5B94A960"><enum>(a)</enum><header>Establishment of credit</header><text>For purposes of section 46, the generic drugs and biosimilars investment credit for any taxable year is an amount equal to 25 percent of the qualified investment for such taxable year with respect to any qualified facility of an eligible taxpayer.</text></subsection><subsection id="HF7AE9019921045C5A6C537CFC7CFC611"><enum>(b)</enum><header>Qualified investment</header><text>For purposes of this section—</text><paragraph id="HF370A5D1BEC74EDEABED1CBE383F173A"><enum>(1)</enum><header>In general</header><text>The qualified investment for any taxable year is the basis of any qualified property placed in service by the taxpayer during such taxable year which is part of a qualified facility.</text></paragraph><paragraph id="H5416623D1FF9400C8DCF6FD88B3A750C"><enum>(2)</enum><header>Qualified property</header><subparagraph id="H55E1123CE21B439AAD7AF0A0BE06D9B8"><enum>(A)</enum><header>In general</header><text>The term <term>qualified property</term> means property—</text><clause id="HB46838E9093F4746B9EB1D4F0F4815F7"><enum>(i)</enum><text>which is tangible property,</text></clause><clause id="HC6C47FBD595F46D0BDF88428958442F8"><enum>(ii)</enum><text>with respect to which depreciation (or amortization in lieu of depreciation) is allowable,</text></clause><clause id="HF2B17EEC108C4B36AD77678E61A815A7"><enum>(iii)</enum><text>which is—</text><subclause id="H5D79313C6D1A478FB5C3F4063212D512"><enum>(I)</enum><text>constructed, reconstructed, or erected by the taxpayer, or</text></subclause><subclause id="HA6140575D69B469DBDD739454B34B02C"><enum>(II)</enum><text>acquired by the taxpayer if the original use of such property commences with the taxpayer, and</text></subclause></clause><clause id="H7134DC9F86D942829FFC398E9346010D"><enum>(iv)</enum><text>which is used as an integral part of the qualified facility to produce eligible components.</text></clause></subparagraph><subparagraph id="HFC6F4B756AFC40A6B760CF4913B81F60"><enum>(B)</enum><header>Buildings and structural components</header><clause id="H085A2AD24DFF4CCB9672BDEC1AF3612A"><enum>(i)</enum><header>In general</header><text>The term <term>qualified property</term> includes any building or its structural components which otherwise satisfies the requirements of subparagraph (A).</text></clause><clause id="H60C2ECA3431648CDAF15088DFB9C6BA2"><enum>(ii)</enum><header>Exception</header><text>Clause (i) shall not apply with respect to a building or portion of a building used for offices, administrative services, or other functions unrelated to the production of eligible components.</text></clause></subparagraph></paragraph><paragraph id="H5A06CF00BE08468198FB7427982A240D"><enum>(3)</enum><header>Qualified facility</header><text>The term <term>qualified facility</term> means a facility—</text><subparagraph commented="no" display-inline="no-display-inline" id="id3697aefd73c64b849467000c4cc5b0e4"><enum>(A)</enum><text display-inline="yes-display-inline">which is owned (in whole or in part) by the taxpayer,</text></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="id2eb387b69e2c469282453940ce2ab77d"><enum>(B)</enum><text>which is located in the United States or any territory of the United States, and</text></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="idae2fec2f4c2e4713826d87c4afb080a6"><enum>(C)</enum><text display-inline="yes-display-inline">the primary purpose of which is the production of eligible components.</text></subparagraph></paragraph><paragraph id="H58391198D8014A7D98C1BC11BD8D748C"><enum>(4)</enum><header>Coordination with rehabilitation credit</header><text>The qualified investment with respect to any qualified facility for any taxable year shall not include that portion of the basis of any property which is attributable to qualified rehabilitation expenditures (as defined in section 47(c)(2)).</text></paragraph><paragraph id="H19E35228705E41A19532CCCC066375AE"><enum>(5)</enum><header>Certain progress expenditure rules made applicable</header><text>Rules similar to the rules of subsections (c)(4) and (d) of section 46 (as in effect on the day before the date of the enactment of the Revenue Reconciliation Act of 1990) shall apply.</text></paragraph></subsection><subsection id="H03DAB85682504993954AB8AB334866A9"><enum>(c)</enum><header>Definitions</header><text>For purposes of this section—</text><paragraph id="HBBFE8232BCAF4310B588AF2ED76EDD7B"><enum>(1)</enum><header>Eligible taxpayer</header><text>The term <term>eligible taxpayer</term> means any taxpayer which is not a foreign entity of concern (as defined in section 9901(8) of the William M. (Mac) Thornberry National Defense Authorization Act for Fiscal Year 2021 (<external-xref legal-doc="usc" parsable-cite="usc/15/4651">15 U.S.C. 4651</external-xref>).</text></paragraph><paragraph id="H8D86A0920A5B414EB886E5510EBB9CB3"><enum>(2)</enum><header>Eligible component</header><text display-inline="yes-display-inline">The term <term>eligible component</term> has the meaning given such term in section 45BB(c)(1). </text></paragraph><paragraph id="HF168304F41CB465CBA227DA1AD7629F9"><enum>(3)</enum><header>Production</header><text display-inline="yes-display-inline">The term <term>production</term> has the meaning given such term in section 45BB(c)(6). </text></paragraph></subsection><subsection id="H6A37AE0C56904BB9990A7EB16F50805B"><enum>(d)</enum><header>Termination of credit</header><text>The credit allowed under this section shall not apply to property the construction of which begins after December 31, 2028.</text></subsection><subsection commented="no" display-inline="no-display-inline" id="id1E05106761194950AE012649C0B2CA25"><enum>(e)</enum><header display-inline="yes-display-inline">Regulatory authority</header><text display-inline="yes-display-inline">The Secretary shall prescribe such regulations and other guidance as are appropriate or necessary to carry out the purposes of this section.</text></subsection></section><after-quoted-block>.</after-quoted-block></quoted-block></subsection><subsection id="H3AEFF4B024CD46D4BFE973DC85A0FCBD"><enum>(b)</enum><header>Elective payment</header><paragraph commented="no" display-inline="no-display-inline" id="ida0221e27467445cbb75f33c6f67a0332"><enum>(1)</enum><header>In general</header><text display-inline="yes-display-inline"><external-xref legal-doc="usc" parsable-cite="usc/26/6417">Section 6417(b)</external-xref> of the Internal Revenue Code of 1986, as amended by section 2(b) of this Act, is further amended by adding at the end the following new paragraph:</text><quoted-block style="OLC" display-inline="no-display-inline" id="HB5543778C41C41508A7C8241273F9928"><paragraph id="H03673CB415004289B3ED102794B9CE67"><enum>(14)</enum><text display-inline="yes-display-inline">The generic drugs and biosimilars investment credit determined under section 48F.</text></paragraph><after-quoted-block>.</after-quoted-block></quoted-block></paragraph><paragraph commented="no" display-inline="no-display-inline" id="idC9AF58CD72C9413E8428615CB9784531"><enum>(2)</enum><header>Election with respect to other entities</header><text>Paragraph (1) of section 6417(d) of such Code, as amended by this Act, is further amended—</text><subparagraph commented="no" display-inline="no-display-inline" id="id18F2583F191A4C3B88141E01DAD0BEC1"><enum>(A)</enum><text display-inline="yes-display-inline">by redesignating subparagraph (F) as subparagraph (G),</text></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="id715308C165E64E4A9B57173078CBAFCC"><enum>(B)</enum><text>by striking <quote>or (E)</quote> each place it appears in subparagraph (G), as so redesignated, and inserting <quote>(E), or (F)</quote>, and</text></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="id393B08757E9B4A418517354590B1836B"><enum>(C)</enum><text>by inserting after subparagraph (E) the following new subparagraph:</text><quoted-block style="OLC" display-inline="no-display-inline" id="id0F8337A800D94745984E071D5DC092DC"><subparagraph id="idDDE323A930DD49D6B241BB691C3C33DE"><enum>(F)</enum><header>Election with respect to generic drugs and biosimilars investment credit</header><text>If a taxpayer other than an entity described in subparagraph (A) makes an election under this subparagraph with respect to any taxable year in which such taxpayer has placed in service a qualified facility (as defined in section 48F(b)(3)), such taxpayer shall be treated as an applicable entity for purposes of this section for such taxable year, but only with respect to the credit described in subsection (b)(14).</text></subparagraph><after-quoted-block>.</after-quoted-block></quoted-block></subparagraph></paragraph></subsection><subsection id="id2DF7BBB0E93C4550965DA041861D7BF6"><enum>(c)</enum><header>Transfer of credits</header><text><external-xref legal-doc="usc" parsable-cite="usc/26/6418">Section 6418(f)(1)A)</external-xref> of the Internal Revenue Code of 1986, as amended by this Act, is further amended by adding at the end the following new clause:</text><quoted-block style="OLC" display-inline="no-display-inline" id="idAE94B8CA60D145CA9FE6A054E9921B3B"><clause id="id043E1101F3FE4107B0DDD10C26B6897D"><enum>(xiii)</enum><text>The generic drugs and biosimilars investment credit determined under section 48F.</text></clause><after-quoted-block>.</after-quoted-block></quoted-block></subsection><subsection id="HB1EE8D1C95954607AC1CF37C6345C6BD"><enum>(d)</enum><header>Conforming amendments</header><paragraph id="HBEB7D9567CE94B19BE94AB4F4D7FEAFF"><enum>(1)</enum><text><external-xref legal-doc="usc" parsable-cite="usc/26/46">Section 46</external-xref> of the Internal Revenue Code of 1986 is amended—</text><subparagraph id="H92344F1E11684B47ABE301A41F2FB250"><enum>(A)</enum><text>by striking <quote>and</quote> at the end of paragraph (6),</text></subparagraph><subparagraph id="H3F41D31B466E4060AF29B3427A1997EC"><enum>(B)</enum><text>by striking the period at the end of paragraph (7) and inserting <quote>, and</quote>, and</text></subparagraph><subparagraph id="H315BCBF1969C402E8C34ACF62266376B"><enum>(C)</enum><text>by adding at the end the following new paragraph:</text><quoted-block style="OLC" id="H64E44CA61099449080C1F5C020A9DD55"><paragraph id="HC9B22DF8792C4C02A84C68364D5D17B5"><enum>(8)</enum><text>the generic drugs and biosimilars investment credit.</text></paragraph><after-quoted-block>.</after-quoted-block></quoted-block></subparagraph></paragraph><paragraph id="H00425D46BA6246D780051AC5131BA766"><enum>(2)</enum><text>Section 49(a)(1)(C) of such Code is amended—</text><subparagraph id="H452887A5FF85473799C01ECA967F2556"><enum>(A)</enum><text>by striking <quote>and</quote> at the end of clause (vii),</text></subparagraph><subparagraph id="H48557F536F3D4C2FB3765928265F4BCD"><enum>(B)</enum><text>by striking the period at the end of clause (viii) and inserting <quote>, and</quote>, and</text></subparagraph><subparagraph id="H06AF639C9B734ACDB342DAFB9394ED50"><enum>(C)</enum><text>by adding at the end the following new clause:</text><quoted-block style="OLC" id="HD4644F225446453AA04D6CD48879C9EE"><clause id="H0FC8785FA0CE43A6B2CB8336C18B28CA"><enum>(ix)</enum><text>the basis of any qualified property which is part of a qualified facility under section 48F.</text></clause><after-quoted-block>.</after-quoted-block></quoted-block></subparagraph></paragraph><paragraph id="HDD1EB200224944B185F18BFCC22293A9"><enum>(3)</enum><text>The table of sections for subpart E of part IV of subchapter A of chapter 1 is amended by inserting after the item relating to section 48E the following new item:</text><quoted-block style="OLC" id="H967D09FBD79743308F67FCF6A6A22DE9"><toc regeneration="no-regeneration"><toc-entry level="section">48F. Generic drugs and biosimilars investment credit.</toc-entry></toc><after-quoted-block>.</after-quoted-block></quoted-block></paragraph></subsection><subsection id="HF2902CA8F4EE415BB13978EAD076E0A2"><enum>(e)</enum><header>Effective date</header><text>The amendments made by this section shall apply to property placed in service after December 31, 2026.</text></subsection></section></legis-body></bill> 

